Trial reportInternational wound journal2015
Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly.
Trial report in International wound journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Efficacy and Safety of Pentoxifylline for Venous Leg Ulcers: An Updated Meta-Analysis.The international journal of lower extremity wounds · 2024Pooled it
- Is low-molecular-weight heparin beneficial to chronic ulcers? A meta-analysis of randomised control trials.International wound journal · 2017Pooled it
- Evaluation of heparin gel's effects on stage II pressure ulcers: a randomized controlled trial.European journal of medical research · 2025Trial
- Doxycycline speeds up healing of chronic venous ulcers.International wound journal · 2015Trial
- The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs.Drug design, development and therapy · 2014Trial
- CGF Treatment of Leg Ulcers: a Randomized Controlled Trial.Open medicine (Warsaw, Poland) · 2019Article
- PredyCLU: a prediction system for chronic leg ulcers based on fuzzy logic; part I - exploring the venous side.International wound journal · 2016Article
- A Heparin-Mimicking Block Copolymer Both Stabilizes and Increases the Activity of Fibroblast Growth Factor 2 (FGF2).Biomacromolecules · 2016Article
- Effectiveness of prostaglandin E1 in patients with mixed arterial and venous ulcers of the lower limbs.International wound journal · 2016Article
- Trophic effects of polynucleotides and hyaluronic acid in the healing of venous ulcers of the lower limbs: a clinical study.International wound journal · 2016Article
- Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines.International wound journal · 2016Article
- Effects of a new nutraceutical substance on clinical and molecular parameters in patients with chronic venous ulceration.International wound journal · 2016Article
- The Role of Matrix Metalloproteinases in Diabetic Wound Healing in relation to Photobiomodulation.Journal of diabetes research · 2016Review
- Role of matrix metalloproteinases in non-healing venous ulcers.International wound journal · 2015Article
- An unusual evolution of a case of Klippel-Trenaunay syndrome.Open medicine (Warsaw, Poland) · 2015Article
- Pyoderma gangrenosum-like skin changes after subcutaneous administration of low molecular weight heparin.Human vaccines & immunotherapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous ulcers are common, especially in the elderly, accounting for more than 50% of all lower extremity ulcers with important socioeconomic problems. Improving extracellular matrix functioning, by heparin administration, seems to be a way to support wound healing. A total of 284 patients with venous ulcers were recruited in a 4-year period. All patients were subjected to the most appropriate treatment after considering their preference (compression therapy followed or not by vein surgery). Patients were randomised into two groups of 142 persons in each (group A and group B as cases and controls, respectively). Patients of group A, in addition to the basic treatment as described earlier, received administration of nadroparin 2850 IU/0.3 ml through subcutaneous injection once a day for 12 months, whereas group B patients received basic treatment alone. Healing was assessed by means of direct ulcer tracing with computerised planimetry. Group A showed a healing rate of 83·80% at 12 months, whereas that of group B was 60·56%. Results by age group surprisingly showed that the group of older patients took the most advantage from long-term treatment with low molecular weight heparin; this group also had lowest recurrence rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.